<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730262</url>
  </required_header>
  <id_info>
    <org_study_id>TLN-4601-201</org_study_id>
    <nct_id>NCT00730262</nct_id>
  </id_info>
  <brief_title>Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thallion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thallion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat
      patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line
      systemic therapy post surgery/radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of TLN-4601 in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1).</measure>
    <time_frame>6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of TLN-4601 in patients with recurrent GBM</measure>
    <time_frame>Maximum 13 months from date of initial infusion of TLN-4601 (Day 1, Cycle 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLN-4601</intervention_name>
    <description>14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period</description>
    <arm_group_label>Single-Arm</arm_group_label>
    <other_name>Formerly ECO-4601</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Glioblastoma Multiforme (GBM)

          -  Prior treatment with radiation and one first line systemic therapy (including
             temozolomide or other chemotherapy, immunotherapy, targeted therapy or combination
             therapies), followed by measurable and unequivocal evidence of tumor progression or
             recurrence

          -  Age ≥ 18 years

          -  ECOG ≤ 2

          -  Normal organ and marrow function as defined below:

               -  leukocytes ≥3 x 109/L

               -  absolute neutrophil count ≥1.5 x 109/L

               -  platelets ≥100 x 109/L

               -  hemoglobin ≥90 g/L

               -  total bilirubin ≤2.5 X institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal

               -  creatinine ≤1.0 X institutional upper limit of normal

        Exclusion Criteria:

          -  Patients with a life expectancy &lt; 12 weeks

          -  Patients with a documented history of HIV, active hepatitis B or C infections

          -  Female patients who are pregnant or lactating

          -  Patients in whom a proper central line (Portacath-like device) cannot be established

          -  Patients with a known hypersensitivity to farnesylated dibenzodiazepinone or
             polysorbate 80

          -  Patients with uncontrolled hypotension

          -  Patients with concomitant therapy of therapeutic coumadin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Mason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Pencer Brain Tumor Center, Princess Margaret Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sloan-Kettering Institute for Cancer Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pencer Brain Tumor Center, Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>December 29, 2009</last_update_submitted>
  <last_update_submitted_qc>December 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Didier Reymond, MD / Vice-President Medical and Clinical Affairs</name_title>
    <organization>Thallion Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>Glioblastoma Multiforme (GBM)</keyword>
  <keyword>Phase II</keyword>
  <keyword>Brain Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 6, 2013</submitted>
    <returned>March 8, 2013</returned>
    <submitted>April 23, 2013</submitted>
    <returned>May 30, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

